NovaPep
Retatrutide Pen
10 mg pen, 3 mL
Research use only. NovaPep supplies research-grade peptides for laboratory and in-vitro work only, not for human or veterinary use. By continuing you confirm you are 18 or older and ordering for research.
NovaPepIn stock in Australia, batch certificate ready
Buy reta peptide Australia stock online from NovaPep in 10 mg, 20 mg and 30 mg retatrutide research vials, tested on every lot. Reta peptide is the short name for retatrutide, a synthetic 39 amino acid peptide developed by Eli Lilly under the code LY3437943 that engages the GIP, GLP-1 and glucagon receptors at once. A C20 fatty diacid on its chain binds it to albumin, and it is still investigational, with no approved medicine anywhere. In Australia it is supplied as lyophilised retatrutide vials of 10 mg, 20 mg or 30 mg, sent from stock held locally with every lot fully traceable. You will find it in our metabolic peptide range, identified by C221H342N46O68, 4731.3 g/mol and CAS 2381089-83-2. Every lot is verified by mass spectrometry and measured by HPLC, and you can read the certificate in the COA library before finalising your cart. For in vitro dilution series, the retatrutide calculator turns your chosen diluent volume into a concentration. Adding tirzepatide to the same order lets you compare a dual agonist with the triple. Vials are shipped as dry powder without diluent, so include bacteriostatic water or pick the starter kit that bundles water and a syringe. Store the unopened vial frozen at -20 °C. Sold as a research reagent to adult customers 18 and over.
For laboratory research use only. Not for human or veterinary use. Not TGA approved. See the NovaPep research use policy.
Researchers describe retatrutide as a triple agonist because this investigational peptide mimics hormones and activates three receptors from the gut and pancreas simultaneously. In plain terms, it is one synthetic chain designed to carry out the signalling of glucagon, GIP and GLP-1 all at once. Buy Retatrutide online in Australia as a 10 mg, 20 mg or 30 mg research vial, with the lot certificate published before you order.
Retatrutide comes from Eli Lilly, also the developer of tirzepatide, and unites the receptors for three digestive and pancreatic hormones in a single molecule. Its structure appeared in print in the early 2020s, and although it has advanced through Phase 2 and Phase 3 trials, it is still investigational and has no TGA approval. In the lab it addresses a single focused question, which is what happens once all three pathways are switched on together.
No other compound in our metabolic peptides collection reaches the glucagon receptor in addition to both incretin receptors. The NovaPep vial is a research reagent unconnected to any medicine, and our article on whether retatrutide is available in Australia explains its regulatory position in full.
Normally each of those receptors responds to its own natural messenger. After eating, L cells in the lower intestine release GLP-1, which triggers glucose-dependent insulin release and slows stomach emptying. GIP is produced by K cells further up in the duodenum, where it likewise boosts insulin secretion and also shapes how adipose tissue stores lipid. Glucagon works almost in reverse. Pancreatic alpha cells produce it to signal the liver to release glucose between meals, and it increases energy expenditure and fat oxidation in the liver. Combining one hormone that raises glucose with two that lower it seems counterintuitive, yet that balance is the whole concept, with the incretin arms holding glucose steady while the glucagon arm adds energy use.
One point is often misread. Retatrutide is not just a more powerful GLP-1 compound. In cell assays its strongest activity is at GIP, and its GLP-1 and glucagon activity is weaker than that of the native hormones. For receptor studies, this favours cAMP readouts in separate cell lines each expressing a single receptor instead of one mixed line, so each response can be traced to the correct arm. When labs ask which peptide makes the best partner for retatrutide in a comparison set, we suggest a control that hits none of the three targets, for example cagrilintide, an amylin analogue.
The discovery work was published by a Lilly team in Cell Metabolism in 2022, with Tamer Coskun as first author. In mice fed a high-fat diet to induce obesity, the compound reduced body weight and improved glycaemic control. The authors attributed the additional loss to glucagon receptor activity increasing energy expenditure, layered over the lower food intake produced by the two incretin receptors. Treated animals also showed reduced liver triglycerides and plasma ALT. Studies in people came next. A phase 2 obesity trial reported in NEJM in 2023 followed 338 adults over 48 weeks, and lead investigator Ania Jastreboff found that roughly two thirds of participants on the highest dose lost 20% or more of their body weight. Larger phase 3 programmes known as TRIUMPH and TRANSCEND have since tested it in much bigger populations, always within registered clinical studies. For a trial by trial account, see the full retatrutide guide. To run this kind of in vitro work, buy Retatrutide online in Australia from lots tested by HPLC and mass spectrometry.
| Product | Retatrutide (LY3437943) |
|---|---|
| Sizes | 10 mg vial, 20 mg vial, 30 mg vial |
| Structure or sequence | Triple agonist peptide of the GIP, GLP-1 and glucagon receptors, built on a GIP-based backbone with a C20 fatty diacid on a lysine |
| Chain length | 39 amino acids |
| Formula | C221H342N46O68 |
| Molar mass | 4731.3 g/mol |
| CAS | 2381089-83-2 |
| Format | Lyophilised powder in a sealed glass vial with white cap |
| Analysis | Mass spectrometry for identity and HPLC for purity, with a published certificate for each lot |
| In the box | A single vial holding 10, 20 or 30 mg of retatrutide, shipped without diluent (bacteriostatic water is sold separately) |
| Storage | Powder at -20 °C protected from light and moisture, solution at 2 to 8 °C |
| Stock | In stock |
| Intended use | Laboratory in vitro research only |
You receive one white-capped glass vial containing a dry white cake or loose powder of retatrutide in the fill you selected, whether 10, 20 or 30 mg. It contains no liquid and no other active ingredient. The compound began as LY3437943, an Eli Lilly candidate presented in 2022 as a single peptide built to engage three hormone receptors, and this lyophilised vial is the base format behind our pen and starter kit.
Retatrutide is the one compound in our catalogue that acts as a GIP, GLP-1 and glucagon triple agonist, making it the choice for in vitro studies spanning all three receptors. All three sizes carry HPLC results for each lot, and you can read the retatrutide vs tirzepatide guide to see how it compares with the dual agonist.
Like tirzepatide, retatrutide is built on a GIP-derived scaffold. Aminoisobutyric acid (Aib) and alpha-methyl amino acids guard the positions DPP-4 attacks, the chain terminates in an amide, and a single lysine carries a spacer joined to a C20 fatty diacid. That lipid tail binds albumin reversibly, which explains the reported half-life of about six days.
On the certificate, look for a mass of 4731.3 g/mol and CAS 2381089-83-2. No lot is released until it passes mass spectrometry and HPLC, and every report appears in the COA library, where you can search by the lot code printed on your vial.
Because the vial holds only powder, it needs a diluent such as bacteriostatic water. Allow the vial to warm to room temperature, let the water run down the glass and roll the vial gently. Adding 2 mL to the 10 mg vial gives 5 mg/mL, and adding 3 mL to the 30 mg vial gives 10 mg/mL. For any other volume, use the retatrutide calculator. When you buy Retatrutide online in Australia, orders paid by 3pm on a business day are dispatched the same afternoon.
Keep the unopened vial in a freezer at -20 °C, dry and away from light, although the powder copes with brief periods at room temperature during shipping. Once in solution, store it at 2 to 8 °C, preferably in aliquots, and use it within 28 days. Do not refreeze the same preparation. Solution shelf life is explained in the storage guide.
Each peptide is 39 amino acids long, with a GIP-type sequence and a C20 fatty chain. What separates them is the glucagon receptor, which retatrutide activates and tirzepatide leaves alone. With structures this similar, running both allows a lab to pin down what the glucagon pathway contributes. According to in vitro data, retatrutide is more potent than native GIP at the GIP receptor and less potent than the natural hormones at the GLP-1 and glucagon receptors. Tirzepatide is available as a 2 mg vial.
If you want a cellular rather than receptor perspective, MOTS-c is a useful addition, and the pre-filled retatrutide pen supplies the same molecule ready dissolved.
You may find this vial listed as retatrutide, under its development code LY3437943 or by the short name reta, so it also turns up as reta-peptide, peptide reta or just reta peptides. Some supplier lists put it under peptides reta or call it peptide retatrutide. Every one of these names describes a single 39 residue chain with CAS 2381089-83-2 and the formula C221H342N46O68.
The receptors bring their own terms. In vitro, retatrutide is studied as a triple agonist at the GLP-1 (glucagon-like peptide-1), GIP and glucagon receptors. GIP was originally called gastric inhibitory polypeptide and was later renamed glucose-dependent insulinotropic polypeptide, with its sequence unchanged.
So is retatrutide legal in Australia as a medicine? Not at this stage. As of October 2026 the Australian Register of Therapeutic Goods lists no product containing it. No approved version can be prescribed by a doctor, and the TGA included it in its 2026 warnings on unapproved peptides. The TGA said it should not be used outside a clinical trial. In the United States, Lilly stated in July 2026 that it intends to submit its application in the first quarter of 2027 after completing its manufacturing and quality data package. Australian approval would require a separate TGA evaluation, and no local submission date has been announced.
Since there is no registered product, pharmacies have nothing to dispense, and Australian laboratories obtain the compound from chemical suppliers. NovaPep holds all three fills in local stock as a research reagent that adults 18 and over can order online, and it is not for human or veterinary use. When you buy retatrutide in Australia from us, the vial's lot code links to an independent report on identity and purity, and our explainer on what retatrutide is covers how the compound was designed.
Three fills, one specification. Choose the 10 mg vial for method development and pilot work. The 20 mg vial costs less per mg and suits labs with a settled method. The 30 mg vial offers the lowest unit cost for established programmes that will finish the vial within 28 days of reconstitution. Making this molecule is demanding, since it involves 39 residues, several non-natural amino acids and a carefully controlled acylation step followed by tight purification.
Where stock permits, ordering multiple vials from the same lot keeps traceability simple because the whole series sits under one certificate. If you want powder, diluent and a syringe in one carton, the retatrutide starter kit is the simpler order. Only adults 18 and over may order, and age is confirmed before checkout.
NovaPep runs entirely online with no storefront or collection point, supplying the whole country. Wherever your lab is based, you order retatrutide through this page from the same stock with the lot certificate on display, and payment received before 3pm on a business day is dispatched that afternoon. Labs sourcing research peptides in Sydney use this same page.
NovaPep sells retatrutide only online, without a shop or pickup counter, and delivers from a single Australian stock to all states and territories. Whatever your location, the vials come from the same tested lots. Orders paid for before 3pm on a business day are sent that afternoon with tracking.
Yes. Before release, each lot is tested by mass spectrometry against the expected 4731.3 g/mol and by HPLC for purity. The certificate sits under the lot code printed on your vial, and you can view it in the COA library before ordering.
Begin with the 10 mg vial for method development or a pilot. Step up to 20 mg when your method is settled, or take 30 mg for the lowest price per milligram. Pick the size you will use up within 28 days of reconstitution.
This 39 amino acid peptide switches on three hormone receptors together, GIP, GLP-1 and glucagon. Its fatty chain links it to albumin and greatly extends its half-life.
Sealed lyophilised vials, with the 30 mg fill the cheapest per milligram. Diluent is not included, so add bacteriostatic water or choose the starter kit instead.
Used in cell-based receptor pharmacology, metabolic mouse models and head to head work against mono and dual agonists. For laboratory use only.
Equal length, the same GIP foundation and one added target, the glucagon receptor. Tirzepatide stays the dual agonist benchmark.
Keep the sealed vial in the freezer and the solution in the fridge, divided into aliquots. Never freeze and thaw one preparation more than once.
Every lot undergoes mass spectrometry and HPLC, and each certificate is published for viewing in the COA library.
Retatrutide is a 39 residue triple agonist built on a GIP-derived scaffold. It activates the GIP, GLP-1 and glucagon receptors, with its strongest in vitro activity at GIP. A C20 fatty diacid binds albumin reversibly, which explains the reported half-life of about six days.
Look for documentation you can verify and stock held locally. The best retatrutide peptide for research is one where you can match the mass and HPLC data to the vial before paying, and the best place to buy retatrutide peptides is a supplier that publishes every lot. NovaPep posts every certificate in the COA library and ships from Australia.
For lab work, the best peptide stack with retatrutide is a set of comparators, not a blend. Tirzepatide, sold as a 2 mg vial, drops the glucagon arm while keeping an almost identical structure, and MOTS-c brings a cellular perspective. Add bacteriostatic water to complete the order. Every compound is supplied for in vitro research only.
In a lab order, the best peptides to stack with reta are comparators that isolate one receptor at a time, such as tirzepatide or cagrilintide. Searches for the best peptide to take with reta, or the best peptides to take with reta, usually concern personal use. NovaPep gives no such advice, and every vial is for in vitro research only.
That is a dosing question, and NovaPep does not answer it for people or animals. There is no best time to take reta peptide from a research supplier, because the vials are for laboratory work only. The timing that matters at the bench is storage, so keep reconstituted solution at 2 to 8 °C and never refreeze it.
Retatrutide is a metabolic research peptide, not a skin compound, and we make no cosmetic claims for it. Posts about reta peptide skin sensitivity come from unregulated personal use, not lab findings. Lists of the best peptides for weight loss, retatrutide among them, mix research compounds with prescription medicines, so read them with care. For skin work, browse our skin and hair peptides.
NovaPep
10 mg pen, 3 mL
NovaPep
2 mg vial
NovaPep
NovaPep
Pen, 3 mL